Share this article
SUZHOU, China, June 2, 2021 /PRNewswire/
On May 31, 2021, Porton Biologics Ltd. (hereinafter referred to as Portonbio) announced a strategic cooperation with Nanjing KAEDI Biotech, Inc. (hereinafter referred to as KAEDI). Portonbio will offer CMC services for KAEDI s CAR-T cell therapies with its end-to-end CDMO platform for gene and cell therapies to help accelerate their development process.
According to the agreement, Portonbio, as an exclusive CDMO partner, will provide KAEDI with CMC services for multiple CAR-T projects
,
including the process development and manufacturing of plasmids, viral vectors and CAR-T cells and IND filling (CMC part) support services. The indication of the first project of our collaboration, KD-025 CAR-T, is liver cancer and glioma. The results of its preclinical research have been published in the leading international journal of tumor immunotherapy and ASCO (American Society of Clinical Oncology). At present, a multi-cente
China Digest: GL Ventures backs Porton Biologics; Smartbi nets $15m funding
Visual from Freedigitalphoto.net
April 20, 2021
Suzhou Porton secured 400 million yuan ($62 million) from GL Ventures and others in a Series A round, while Smartbi has raised 100 million yuan ($15 million) in a Series B+ round of financing.
GL Ventures invests in Porton Biologics
Suzhou Porton Biologics Ltd., a subsidiary of Porton Pharma Solutions that focuses on gene and cell therapy services, has secured 400 million yuan ($62 million) in a Series A round.
The financing attracted leading investors like state-backed CMC-SDIC Capital, Hillhouse Capital’s venture unit GL Ventures, HM Capital, Huashan Ruilian and Momentum Venture, according to a company statement on Tuesday.